Design and biological evaluation of 99m Tc-N 2 S 2-Tat (49–57)-c (RGDyK): A hybrid radiopharmaceutical for tumors expressing α (v) β (3) integrins

Design and biological evaluation of 99m Tc-N 2 S 2-Tat (49–57)-c (RGDyK): A hybrid radiopharmaceutical for tumors expressing α (v) β (3) integrins

BE Ocampo-García, CL Santos-Cuevas… - Nuclear medicine and …, 2013 - Elsevier

... One hundred microliters (1 mM) of unlabeled cRGDfK (Bachem) was intraperitoneally
administered one hour ... radiopharmaceutical compared to 12 for the conventional 99m Tc-RGD
peptide (Table 2 ... 4). The thyroid was found to have a normal biodistribution of RGD peptides. ...

Peptide synthesis, peptide modification and peptide library synthesis, please contact:

Eva He

eva@pepmic.com

Pepmic Co., Ltd

www.pepmic.com